Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist
- 18 August 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (20) , 3736-3745
- https://doi.org/10.1021/jm000133v
Abstract
Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7, 8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.Keywords
This publication has 15 references indexed in Scilit:
- Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp MimeticJournal of Medicinal Chemistry, 1999
- Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1998
- Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) AntagonistsJournal of Medicinal Chemistry, 1997
- Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor AntagonistsJournal of Medicinal Chemistry, 1997
- A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.Journal of Clinical Investigation, 1997
- Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.Endocrinology, 1996
- Review Cardiovascular & Renal; Recent Developments in Glycoprotein llb/llla AntagonistsExpert Opinion on Therapeutic Patents, 1995
- Osteoporosis in MenEndocrine Reviews, 1995
- Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.Endocrinology, 1993
- Receptor-specific antiplatelet therapy.Circulation, 1989